<DOC>
	<DOCNO>NCT02450721</DOCNO>
	<brief_summary>Aim present study investigate molecular clinical marker patient atherosclerotic carotid stenosis ( ACAS ) ischemic stroke acute phase .</brief_summary>
	<brief_title>Clinical Laboratory Biomarkers Patients With Atherothrombotic Stroke</brief_title>
	<detailed_description>Background : Laboratory biomarkers atherosclerosis valuable decision operative treatment patient mild severe atherosclerotic carotid stenosis ( ACAS ) high stroke risk . However nowadays establish instrument personalize atherothrombotic stroke diagnostics . Aim present study access atherosclerosis biomarkers serum level patient ACAS ischemic stroke/ transient ischemic attack ( TIA ) acute phase . Main objective study To explore informative biomarkers determine risk stroke patient significant ACAS . Secondary objectives 1 . To investigate association degree neurological cognitive deficit , feature disease , severity brain lesion accord neuroimaging data concentration lipoprotein -associated phospholipase A2 ( LP-PL-A2 ) , high sensitive C- reactive protein ( hsCRP ) , pregnancy-associated plasma protein A ( PAPP-A ) , asymmetric dimethylarginine ( ADMA ) , lipoprotein ( ) patient atherothrombotic stroke . 2 . To find valuable laboratory biomarkers atherosclerosis , compare clinical objective data make decision inclusion biomarkers routine practice screen test atherosclerotic plaque instability stroke risk prediction decision operative treatment patient ACAS . Design Methods A single-blind cross-sectional trial perform investigate laboratory biomarkers atherosclerosis patient atherosclerotic stenosis internal carotid artery 50-99 % , healthy volunteer . Randomizing blind technique : laboratory scientist statistician information belonging biomaterials patient group study . Examination patient include history taking , neurological examination , duplex ultrasound , mini mental score examination ( MMSE ) , enzyme-linked immunosorbent assay ( ELISA ) perform atherosclerosis biomarkers serum level measurement ( LP-PL-A2 , PAPP-A , ADMA , hsCRP blood lipid profile ) .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Carotid Artery Diseases</mesh_term>
	<criteria>Acute stroke 5099 % atherosclerotic carotid artery stenosis Acute atherothrombotic stroke/TIA ( accord TOASTcriteria ) within first 3 day vascular event risk factor nonatherothrombotic stroke ( accord TOASTcriteria ) cancer exacerbation decompensated chronic disease infection acute cardiovascular disease large operation 1 month enrollment Cortexin , Actovegin , Cerebrolysin , Erythropoetin administration 1 week enrollment . Stable ACAS 5099 % atherosclerotic carotid artery stenosis history vascular event one month enrollment risk factor nonatherothrombotic stroke ( accord TOASTcriteria ) cancer exacerbation decompensated chronic disease infection acute cardiovascular disease large operation 1 month enrollment Cortexin , Actovegin , Cerebrolysin , Erythropoetin administration 1 week enrollment . Control group intima medium thickness le 1mm history stroke/TIAs risk factor nonatherothrombotic stroke ( accord TOASTcriteria ) cancer exacerbation decompensated chronic disease infection acute cardiovascular disease large operation 1 month enrollment Cortexin , Actovegin , Cerebrolysin , Erythropoetin administration 1 week enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>atherosclerosis</keyword>
	<keyword>biomarkers</keyword>
	<keyword>carotid artery stenosis</keyword>
	<keyword>ischemic stroke .</keyword>
</DOC>